Preclinical pharmacology of neuroleptics: focus on new generation compounds.
This article reviews the preclinical pharmacology of neuroleptics, with focus on the newer generation compounds: clozapine, risperidone, olanzapine, sertindole, and quetiapine. All of these newer compounds are considered to be atypical neuroleptics, based on certain criteria, which are reviewed. Several hypotheses about the molecular mechanisms that explain atypicality are considered. Finally, the in vitro receptor binding data presented for these and some older compounds are related to the therapeutic and adverse effects of these drugs.
Richelson
E
E
Department of Psychiatry, Mayo Clinic and Foundation, Jacksonville, Fla. 32224, USA.
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D004347:Drug Interactions; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000187:drug effects; D011968:Receptors, Histamine / Q000187:drug effects / Q000378:metabolism; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000378:metabolism; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism; D013329:Structure-Activity Relationship
D014150:Antipsychotic Agents; D065127:Dopamine D2 Receptor Antagonists; D011942:Receptors, Adrenergic, alpha; D017448:Receptors, Dopamine D2; D011968:Receptors, Histamine; D011976:Receptors, Muscarinic; D011985:Receptors, Serotonin